摘要
目的探讨沙库巴曲缬沙坦对慢性心力衰竭患者的疗效及对患者心功能、血清沉默调节蛋白-4(Sirtuin-4)和Beclin-1水平的影响。方法选取2019年1月—2021年9月内蒙古自治区国际蒙医医院收治的60例慢性心力衰竭患者作为研究对象,依据随机数表法将患者分为对照组和观察组,每组30例。对照组采用贝那普利治疗,观察组采用沙库巴曲缬沙坦治疗,比较两组患者治疗前后左室收缩末期容积(LVESV)、左室舒张末期容积(LVEDV)、左室射血分数(LVEF)和血清Sirtuin-4及Beclin-1的水平,以及总有效率、住院次数、平均住院天数、不良反应发生率。结果观察组有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组LVEF、LVESV及LVEDV水平比较,差异无统计学意义(P>0.05);治疗后,两组LVEF、LVESV及LVEDV水平均高于治疗前,且观察组LVEF、LVESV及LVEDV水平高于对照组,差异有统计学意义(P<0.05)。治疗前,两组Sirtuin-4及Beclin-1水平比较,差异无统计学意义(P>0.05);治疗后,观察组Sirtuin-4及Beclin-1水平低于对照组,差异有统计学意义(P<0.05)。观察组住院次数和平均住院天数均少于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦治疗慢性心力衰竭疗效确切,其能改善患者心功能,降低患者血清Sirtuin-4及Beclin-1水平,减少住院次数和平均住院天数,该方法安全性佳,值得临床应用。
Objective To analyze the efficacy of sacubitril/valsartan in patients with chronic heart failure and its effect on cardiac function,serum sirtuin-4(Sirtuin-4)and Beclin-1 levels.Methods Sixty chronic heart failure patients treated from January 2019 to September 2021 in Inner Mongolia International Mongolian hospital were investigated.According to random number table,patients were divided into control group(n=30,benazepril group)and observation group(n=30,sacubitril/valsartan group).The levels of left ventricular end systolic volume(LVESV),left ventricular end diastolic volume(LVEDV),left ventricular ejection fraction(LVEF),serum sirtuin-4 and beclin-1 before and after treatment,the total effective rate,the number of hospitalizations,the average length of stay and the incidence of adverse reactions were compared between the two groups.Results The effective treatment rate in the observation group was higher than control group(P<0.05).Before treatment,the levels of LVEF,LVESV and LVEDV between the two groups were not significantly different(P>0.05),and after treatment,the levels of LVEF,LVESV and LVEDV in the two groups were higher than those before treatment,and the levels of LVEF,LVESV and LVEDV in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Before treatment,serum Sirtuin-4 and Beclin-1 levels between groups were not significantly different(P>0.05);after treatment,serum Sirtuin-4 and Beclin-1 levels in the observation group were lower than control group(P<0.05).The number of hospitalizations and the average hospitalization days in the observation group were less than those in the control group(P<0.05).There was no difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sacubitril/valsartan has a defi nite curative effect in the treatment of chronic heart failure.It can improve the heart function of patients,reduce the serum levels of Sirtuin-4 and Beclin-1,and reduce the number of hospitalizations an
作者
关敬之
王飞飞
戴文俊
袁少飞
石磊
GUAN Jing-zhi;WANG Fei-fei;DAI Wen-jun;YUAN Shao-fei;SHI Lei(Department of Pharmacy,Inner Mongolia International Mongolian Hospital,Hohhot Inner Mongolia 010065,China;Department of Cardiology,Inner Mongolia International Mongolian Hospital,Hohhot Inner Mongolia 010065,China;Department of Pharmacy,the Second Affiliated Hospital of Baotou Medical College,Inner Mongolia University of Science and Technology,Baotou Inner Mongolia 014030,China;Department of Pharmacy,The First Hospital of Hohhot,Hohhot Inner Mongolia 010030,China)
出处
《中华养生保健》
2023年第3期184-188,共5页
CHINESE HEALTH CARE
